TransCode Therapeutics Inc
RNAZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.75M
Close$
$25.83
1465.3% upside
Current Fair Value
1465.3% upsideUndervalued by 1465.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.75 Million |
|---|---|
| Enterprise Value | $-7,665,288,508.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-52.59 |
| Beta | 1.17 |
| Outstanding Shares | 937,191 |
Return
| Return on Equity | 226.14% |
|---|---|
| Return on Assets | -41.47% |
| Return on Invested Capital | 0.01% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -468.49 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.09 |
| Debt to Equity | -0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.74%▲ 0.37% |
|---|---|
| Total Invested | $217,591▼ 18.10% |
| Investors Holding | 9▲ 2.00% |
ESG Score
No data
About TransCode Therapeutics Inc
2,021 employees